(As of 6/30/2025)

BMO ARK Genomic Revolution Fund Advisor Series

(Health Care Equity)
Inception Return
(11/4/2022)
-10.97 %
YTD Return -2.76 %
NAVPS
(7/10/2025)
$7.36
Change ($0.01) / -0.17 %
Growth of $10,000 (As of June 30, 2025)
MER 1.97 %
Assets ($mil) $5.17
Rank (1Yr) 5/55
Std Dev (3Yr) -
Volatility Ranking (3Yr) -
RRSP Eligibility Yes
Load Back Fee Only
Max Front End 5.00 %
Max Back End -
Sales Status Open
 
Objective
This fund’s objective is to provide long-term capital growth by investing primarily in equity securities of companies involved in disruptive genomic innovation from around the world.
Fund Manager

BMO Investments Inc.

Portfolio Manager

Nicholas Grous, Ark Investment Management LLC

Dan White, Ark Investment Management LLC

Catherine D. Wood, Ark Investment Management LLC

Sub-Advisor
-
 
Asset Allocation
(As of June 30, 2025)
Sector Allocation
(As of June 30, 2025)
Geographic Allocation
(As of June 30, 2025)
Top 10 Holdings
NameAssetSectorGeographicPercent
CRISPR Therapeutics AGInternational EquityHealthcareOther European9.61%
Tempus AI Inc Cl AUS EquityHealthcareUnited States9.27%
Twist Bioscience CorpUS EquityHealthcareUnited States7.37%
Guardant Health IncUS EquityHealthcareUnited States6.59%
Recursion Pharmaceuticals Inc Cl AUS EquityHealthcareUnited States5.56%
Natera IncUS EquityHealthcareUnited States5.32%
Adaptive Biotechnologies CorpUS EquityHealthcareUnited States4.39%
Personalis IncUS EquityHealthcareUnited States4.37%
CareDx IncUS EquityHealthcareUnited States3.85%
Schrodinger IncUS EquityTechnologyUnited States3.77%

Performance Data (As of June 30, 2025)
  Return (%) Annualized Return (%)
Return 1 Mth 3 Mth 6 Mth YTD 1 Yr 3 Yr 5 Yr 10 Yr
Fund 14.96 10.37 -2.76 -2.76 1.98 -    -    -   
Benchmark 0.91 -7.89 -3.97 -3.97 -4.44 5.66 5.14 7.26
Quartile Ranking 1 1 1 1 1 - - -

Calendar Return (%) 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Fund -22.40 11.86 -      -      -      -      -      -      -      -     
Benchmark 9.95 1.42 -1.72 15.28 13.59 17.06 11.82 14.01 -8.68 27.73
Quartile Ranking 4 1 - - - - - - - -

Website powered by © Fundata Canada Inc.
Mutual Fund Data provided by Fundata. | View Terms and Conditions of Use.
BofA Merill Lynch Indices used with permission.
© 2025 Fundata Canada Inc. All rights reserved. | View Privacy Policy | Contact Us.